查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1561496

2024-2032 年按產品、應用、最終用戶和地區分類的藥物器材組合產品市場報告

Drug Device Combination Products Market Report by Product, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球藥物器材組合產品IMARC Group規模達到1,553億美元。藥物輸送系統的技術進步、慢性病盛行率上升、老年人口增加、個人化醫療需求激增、關鍵參與者的策略合作、醫療保健支出擴大、對微創手術的偏好以及在不同治療領域擴大產品應用等都是其中的一些因素。

藥物器材組合產品市場分析：

  • 主要市場促進因素：根據藥物器材組合產品市場分析，慢性病盛行率的上升以及對更有效、更方便的治療方案的需求正在推動對藥物器材組合產品的需求。全球老年人口的快速成長也刺激了藥物器材組合產品市場的成長，隨著老年人產生更多與生活方式相關的健康問題，這增加了對新醫療方法的需求。此外，公司擴大採用個人化醫療方法，包括用於標靶治療的藥物輸送裝置，這進一步積極促進了藥物設備組合產品的市場佔有率。推動藥物器材組合產品市場前景的其他因素包括組合產品開發的監管支援和經濟激勵，以及發展中國家不斷擴大的醫療保健支出。
  • 主要市場趨勢：根據藥物器械組合產品市場研究，藥物器械組合產品最顯著的趨勢是人們對穿戴式藥物輸送設備的興趣日益成長，以改善患者的活動能力和生活品質。推動藥物設備組合產品市場價值的另一個因素是擴大使用智慧型設備來控制患者的依從性和治療反應，並根據需要即時調整劑量和治療方案。與此一致，將數位技術融入產品及其利用物聯網（IoT）的能力增加了患者參與度和結果監測，這進一步推動了藥物器械組合產品的市場需求。除此之外，3D（3D）列印技術的進步為基於患者解剖結構和需求的個人化設備製造創造了新的機會，這有助於藥物設備組合產品市場的預測。
  • 地理趨勢：根據藥物器材組合產品市場研究報告，由於發達的醫療基礎設施、廣泛的研發投資和寬鬆的監管，北美是該行業的領先地區。除此之外，該地區巨大的疾病負擔所支撐的高額醫療支出推動了新興治療替代方案的採用，這進一步推高了藥物器械組合產品的市場價格。鑑於其強大的醫療保健系統以及對品質和安全的關注，歐洲在藥物器材組合產品市場細分方面緊隨其後。另一方面，亞太地區是一個日益成長的市場，受到醫療支出不斷增加、現代治療方法知識不斷增加以及慢性病數量不斷增加的支持，這進一步增加了藥物器械組合產品市場收入。
  • 競爭格局：根據藥物器材組合產品市場統計，市場上的一些主要參與者包括雅培實驗室、百特國際公司、拜耳公司、貝克頓迪金森公司、波士頓科學公司、葛蘭素史克公司、強生公司、美敦力公司plc、Novartis AG、Smith & Nephew plc、Stryker Corporation、Terumo Corporation 等。
  • 挑戰與機會：根據藥物器材組合產品市場概況，市場面臨許多挑戰，包括高水準的監管要求，這可能導致開發時間增加，從而增加成本。確保藥物和器械的兼容性，必須滿足所有安全性和有效性標準，是一個很大的困難。許多相同的因素都提供了創新的機會。特別是提高設備效率和增加患者便利性的新方法。一個有利的機會也是為那些對先進醫療解決方案有潛在需求但尚未解決的國家補充市場。

藥物器材組合產品市場趨勢：

藥物輸送系統的技術進步

新的藥物輸送系統，包括自動注射器、吸入器和輸液泵，正在改變醫療保健的管理方式，使其更加精確、方便和有效。精確、有針對性的藥物輸送使患者能夠達到預期的治療效果，同時將發生藥物不良反應的可能性降到最低。例如，自動注射器的使用極大地改變了患者日常服藥的方式，讓使用者以舒適、簡單的方式自行給藥。此藥物輸送系統有助於提高治療依從性並降低住院費用。針對呼吸系統問題的先進吸入器，例如配備劑量計數器或數位感測器的吸入器，可以提供回饋和監測，使患者能夠獨立管理藥物管理。

慢性病盛行率增加

心血管疾病 (CVD)、糖尿病和癌症等慢性疾病的迅速流行，是滿足複雜治療需求的客製化和創新藥物器材組合產品需求激增的主要因素之一。根據美國國立衛生研究院 (NIH) 的數據，2019 年慢性病死亡人數佔所有死亡人數的 74%； 2010 年，死亡人數大幅資料67%。例如，在澳大利亞，澳洲健康與福利研究所報告稱，47% 的澳洲人至少患有一種慢性疾病，其中 20% 患有兩種或更多慢性疾病。

老年人口不斷增加和對個人化醫療的需求

全球老年人數量的不斷增加以及人類預期壽命的延長將使老年學面臨挑戰，從而需要實施藥物和補救方法，這進一步支持了藥物器械組合產品市場。根據世界衛生組織（WHO）預測，到2030年，每6人中就有1人年齡在60歲以上；屆時，總數將達到14億人。到2050年，該年齡層的人口數量將達到21億，而80歲及以上的人口將攀升至4.26億，是2020年的三倍。

藥物器材組合產品市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品、應用和最終用戶對市場進行了分類。

按產品分類：

  • 藥物洗脫支架
  • 經皮貼劑
  • 點滴幫浦
  • 藥物洗脫球囊
  • 吸入器
  • 其他

經皮貼片代表了領先的細分市場

該報告根據產品提供了詳細的市場細分和分析。這包括藥物洗脫支架、經皮貼片、輸液幫浦、藥物洗脫球囊、吸入器等。根據該報告，經皮貼片代表了最大的部分。

經皮貼片領域受到對非侵入性藥物傳遞方法不斷成長的需求的推動，這些方法提供便利、減輕疼痛並提高患者的依從性。經皮貼片強調以患者為中心的醫療保健解決方案，為傳統口服藥物和注射劑提供了可行的替代方案，特別是對於有針頭恐懼症或吞嚥藥片困難的個人而言。此外，該細分市場也受到貼片技術進步的推動，包括開發新型黏合劑配方和滲透增強劑，增強藥物透過皮膚的吸收，從而實現更高效、更一致的藥物傳遞。此外，心血管疾病、糖尿病和疼痛相關疾病等慢性疾病的盛行率不斷上升，推動了對經皮貼片的需求，因為它們提供緩釋製劑，可確保在較長時間內持續治療藥物水平，從而減少了經皮貼片的使用頻率。

按應用分類：

  • 心血管
  • 糖尿病
  • 癌症治療
  • 呼吸系統疾病
  • 其他

呼吸系統疾病是主要的細分市場

該報告根據應用程式提供了詳細的市場細分和分析。這包括心血管、糖尿病、癌症治療、呼吸系統疾病等。報告稱，呼吸系統疾病佔最大部分。

呼吸系統疾病領域的促進因素是全球呼吸系統疾病的盛行率不斷上升，而空氣污染、吸菸和人口老化等因素又加劇了這種情況。此外，生活方式的改變，包括久坐習慣和不良飲食選擇，導致氣喘、慢性阻塞性肺病（COPD）和呼吸道感染等呼吸道疾病的發生率上升。此外，都市化和工業化導致人們更接觸到環境污染物、過敏原和職業危害，進一步加劇了呼吸道疾病的負擔。此外，人們越來越意識到室內和室外空氣污染對健康的不利影響，推動了對呼吸治療和預防措施的需求，從而促進了市場成長。此外，包括影像模式和生物標記檢測在內的診斷技術的進步，可以實現呼吸系統疾病的早期檢測和干涉，透過改善患者的治療效果和治療效果來推動市場擴張。

按最終用戶分類：

  • 醫院
  • 門診手術中心
  • 其他

醫院代表領先的細分市場

該報告提供了基於最終用戶的詳細市場細分和分析。這包括電子醫院、門診手術中心等。報告稱，醫院佔最大部分。

醫院部門受到對先進醫療設備和技術不斷成長的需求的推動，以加強患者護理、最佳化臨床結果並提高營運效率。醫院正在投資最先進的設備，例如影像系統、手術機器人和病患監護設備，以滿足病患群體不斷成長的醫療保健需求。此外，由於對整合資料管理解決方案的需求推動了電子健康記錄 (EHR) 和健康資訊系統的採用不斷增加，這些解決方案可以簡化工作流程、促進明智的決策並確保遵守監管要求。此外，由於醫療保健相關感染 (HAI) 帶來的持續挑戰以及降低臨床環境風險的需要，醫院正在優先投資於感染控制和患者安全措施。這包括實施先進的消毒技術、抗菌表面和即時監測系統，以防止感染傳播並保障病患的健康。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美市場領先，佔據最大的藥物器材組合產品市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是藥物器械組合產品最大的區域市場。

北美地區受到糖尿病、心血管疾病和癌症等慢性病盛行率日益上升的推動。隨著人口老化的加劇和久坐的生活方式導致慢性病的增加，對創新治療解決方案的需求不斷增加。這一趨勢推動了藥物器械組合產品的採用，這些產品在管理這些複雜的健康問題方面提供了更高的功效和便利性。此外，該地區受益於強力的監管框架和簡化的核准流程，促進了新組合療法的開發和商業化。此外，製藥公司、醫療器材製造商和研究機構之間的策略合作推動了北美地區的創新並加快了產品開發的步伐。這些合作利用該地區強大的研究基礎設施和專業知識來解決未滿足的醫療需求並利用新興市場機會。此外，北美不斷增加的醫療保健支出透過提高先進聯合療法的可及性和促進對研發計劃的投資來支持市場成長。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

  • 藥物器材組合產品市場的主要參與者積極參與策略性舉措，以保持競爭優勢並推動市場成長。這些措施包括廣泛的研究和開發 (R&D) 工作，旨在引入新穎的聯合療法，以改善治療效果並為患者提供便利。此外，公司還致力於透過收購、合作以及與其他行業利益相關者的合作來擴大其產品組合。這些策略聯盟使公司能夠利用互補的專業知識、技術和資源來加速產品開發和市場滲透。此外，主要參與者正在投資行銷和促銷活動，以提高對其產品的認知並增強其市場影響力。此外，我們正在努力加強監管合規性和品質保證流程，以確保產品的安全性和有效性。此外，公司正在透過建立當地製造設施和分銷網路來探索新興市場的機會，以滿足這些地區對組合產品不斷成長的需求。

藥物器材組合產品市場新聞：

  • 2020年6月：雅培宣佈在美國推出其新型藥物器械組合產品FreeStyle Libre 2系統。該系統將雅培的連續血糖監測 (CGM) 技術與穿戴式感測器和行動應用程式整合在一起，使糖尿病患者能夠連續監測其血糖水平，而無需進行指尖採血測試。與先前的模型相比，FreeStyle Libre 2 系統提供了更高的準確性和可靠性，為患者提供對其血糖水平的即時了解，並幫助他們就糖尿病管理做出更明智的決策。
  • 2020 年 8 月：美敦力宣布 FDA 批准其 MiniMed 770G 胰島素幫浦系統用於 2 至 6 歲患有第 1 型糖尿病的兒童。此藥物設備組合產品將胰島素幫浦與連續血糖監測 (CGM) 系統結合，可根據即時血糖讀數自動輸送胰島素。 MiniMed 770G 系統採用先進的演算法，有助於穩定幼兒的血糖水平並降低低血糖的風險，讓照護者安心並改善兒童糖尿病的整體管理。

本報告回答的關鍵問題：

  • 迄今為止，全球藥物器械組合產品市場表現如何，未來幾年將如何表現？
  • 全球藥物器材組合產品市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球藥物器材組合產品市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的藥物器材組合產品市場？
  • 基於產品的市場區隔是什麼？
  • 藥械組合產品市場中哪一款產品最具吸引力？
  • 基於應用的市場區隔是什麼？
  • 藥械組合產品市場最有吸引力的應用是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 藥物器材組合產品市場中哪一個是最具吸引力的最終用戶？
  • 市場競爭結構如何？
  • 全球藥物器材組合產品市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 迄今為止，全球藥物器械組合產品市場表現如何，未來幾年將如何表現？
  • 全球藥物器材組合產品市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球藥物器材組合產品市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的藥物器材組合產品市場？
  • 基於產品的市場區隔是什麼？
  • 藥械組合產品市場中哪一款產品最具吸引力？
  • 基於應用的市場區隔是什麼？
  • 藥械組合產品市場中哪一個應用最有吸引力？
  • 基於最終用戶的市場區隔是什麼？
  • 藥物器材組合產品市場中哪一個是最具吸引力的最終用戶？
  • 市場競爭結構如何？
  • 全球藥物器材組合產品市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球藥物器材組合產品市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 藥物洗脫支架
    • 市場趨勢
    • 市場預測
  • 經皮貼劑
    • 市場趨勢
    • 市場預測
  • 點滴幫浦
    • 市場趨勢
    • 市場預測
  • 藥物洗脫球囊
    • 市場趨勢
    • 市場預測
  • 吸入器
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按應用

  • 心血管
    • 市場趨勢
    • 市場預測
  • 糖尿病
    • 市場趨勢
    • 市場預測
  • 癌症治療
    • 市場趨勢
    • 市場預測
  • 呼吸系統疾病
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 門診手術中心
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Baxter International Inc.
    • Bayer AG
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Medtronic plc
    • Novartis AG
    • Smith & Nephew plc
    • Stryker Corporation
    • Terumo Corporation
Product Code: SR112024A4751

The global drug device combination products market size reached US$ 155.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 284.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032. Technological advancements in drug delivery systems, rising prevalence of chronic diseases, increasing geriatric population, surging demand for personalized medicine, strategic collaborations by key players, expanding healthcare expenditure, preference for minimally invasive procedures, and expanding product applications in diverse therapeutic areas are some of the factors supporting the market growth.

Drug Device Combination Products Market Analysis:

  • Major Market Drivers: As per the drug device combination products market analysis, the rising prevalence of chronic diseases and the requirement for more efficient and convenient treatment alternatives are propelling the demand for drug-device combination products. The drug device combination products market growth is also stimulated by the burgeoning geriatric population worldwide, which has surged the demand for new healthcare approaches, as elderly people are producing more lifestyle-related health problems. Additionally, companies have increasingly adopted approaches to personalized medicine, including drug delivery gadgets for targeted therapy, which is further positively contributing to the drug device combination products market share. Other factors that have fueled the drug device combination products market outlook include regulatory support and economic incentives for combination product development, as well as expanding healthcare spending in developing countries.
  • Key Market Trends: As per the drug device combination products market research, the most substantial trends in the drug-device combination products are the growing interest in wearable drug delivery devices for the patient's mobility and quality of life improvement. Another factor that propels the drug device combination products market value is the increasing use of smart devices to control patient adherence and therapy response and adjust the dose and treatment regime as necessary in real-time. In line with this, the incorporation of digital technology into products and their ability to utilize the Internet of Things (IoT) increases patient engagement and outcomes monitoring, which is further driving the drug device combination products market demand. Apart from this, the progression of three-dimensional (3D) printing technology creates new opportunities for individualizing device manufacturing based on patient anatomy and needs, which is contributing to the drug device combination products market forecast.
  • Geographical Trends: As per the drug device combination products market research report, North America is the leading region in the industry due to the developed healthcare infrastructure, extensive investment in research and development (R&D), and lenient regulation. Besides this, the high health expenditure supported by the massive burden of diseases in the region has driven adoption of new and emerging treatment alternatives, which is further accelerating the drug device combination products market price. Europe is a close follower in the drug device combination products market segmentation, given its strong healthcare systems and focus on quality and safety. On the other hand, the Asia-Pacific region is an increasingly growing market supported by rising health expenditure, increasing knowledge of modern treatment approaches, and a growing number of chronic conditions, which is further boosting the drug device combination products market revenue.
  • Competitive Landscape: As per the drug device combination products market statistics, some of the key players in the market include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.
  • Challenges and Opportunities: As per the drug device combination products market overview, the market has many challenges, including the high level of regulatory requirements, which can lead to an increase in development time and as a result, increase the cost. Ensuring the compatibility of the drug and device, which must meet all safety and effectiveness standards, is a big difficulty. Many of the same factors present opportunities for innovation. In particular, new approaches to increasing the efficiency of devices and increasing the convenience for the patient. A favorable opportunity is also to replenish the market for countries with a potential demand for advanced medical solutions that are not being solved.

Drug Device Combination Products Market Trends:

Technological Advancements in Drug Delivery Systems

New drug delivery systems, including auto-injectors, inhalers, and infusion pumps, are transforming the way healthcare is administered, making it more precise, convenient, and effective. Precise and targeted drug delivery allows patients to achieve the desired therapeutic effect with a minimal likelihood of suffering from adverse drug reactions. For example, using auto-injectors has significantly changed the way patients take medication daily by allowing users to administer it themselves in a comfortable and easy way. This drug delivery system assists with treatment compliance and hospitalization costs cutting. Sophisticated inhalers for respiratory problems, such as those equipped with a dose counter or digital sensors, provide feedback and monitoring, giving patients the power to manage drug administration independently.

Increasing Prevalence of Chronic Diseases

The burgeoning prevalence of chronic diseases, such as cardiovascular disorders (CVDs), diabetes, and cancer, is one of the primary factors that have surged the demand for customized and innovative drug device combination products for complex therapeutic needs. Based on the National Institute of Health (NIH), chronic conditions accounted for 74% of all deaths in 2019; a substantial rise on 67% of deaths in 2010. Mortality data illustrate high prevalence's of chronic conditions among populations. In Australia, for example, Australian Institute of Health and Welfare reports 47% of Australians have at least one chronic disease with 20% bearing 2 or more.

Rising Geriatric Population and Demand for Personalized Medicine

The growing number of geriatric people worldwide and extended human life expectancy will make it challenging to deal with gerontology allowing for the need for medicine implemented and remedy methods, which is further supporting the drug device combination products market. According to the World Health Organization (WHO), 1 of 6 individuals will be aged 60 and above by 2030; at that point, the total number will reach 1.4 billion. By 2050, the number of people in that age category will be 2.1 billion, while the group aged 80 and even older will climb to 426 million, which is three times more in comparison to 2020.

Drug Device Combination Products Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and end user.

Breakup by Product:

  • Drug Eluting Stents
  • Transdermal Patches
  • Infusion Pumps
  • Drug Eluting Balloon
  • Inhalers
  • Others

Transdermal patches represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes drug eluting stents, transdermal patches, infusion pumps, drug eluting balloon, inhalers, and others. According to the report, transdermal patches represented the largest segment.

The transdermal patches segment is driven by the increasing demand for non-invasive drug delivery methods that offer convenience, pain reduction, and improved patient compliance. With an emphasis on patient-centric healthcare solutions, transdermal patches provide a viable alternative to traditional oral medications and injections, particularly for individuals with needle phobia or difficulty swallowing pills. Additionally, the segment is propelled by advancements in patch technology, including the development of novel adhesive formulations and permeation enhancers, which enhance drug absorption through the skin, leading to more efficient and consistent drug delivery. Moreover, the rising prevalence of chronic diseases, such as cardiovascular disorders, diabetes, and pain-related conditions, drives the demand for transdermal patches as they offer sustained release formulations that ensure continuous therapeutic levels of medication over an extended period, reducing the frequency of dosing and minimizing fluctuations in drug concentration in the bloodstream.

Breakup by Application:

  • Cardiovascular
  • Diabetes
  • Cancer Treatment
  • Respiratory Diseases
  • Others

Respiratory diseases represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes cardiovascular, diabetes, cancer treatment, respiratory diseases, and others. According to the report, respiratory diseases represented the largest segment.

The respiratory diseases segment is driven by the increasing prevalence of respiratory disorders globally, exacerbated by factors such as air pollution, smoking, and aging populations. Moreover, lifestyle changes, including sedentary habits and poor dietary choices, contribute to the rising incidence of respiratory ailments such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. Additionally, urbanization and industrialization lead to heightened exposure to environmental pollutants, allergens, and occupational hazards, further escalating the burden of respiratory diseases. Furthermore, the growing awareness about the adverse health effects of indoor and outdoor air pollution drives demand for respiratory therapies and preventive measures, fostering market growth. Moreover, advancements in diagnostic techniques, including imaging modalities and biomarker assays, enable early detection and intervention for respiratory conditions, driving market expansion through improved patient outcomes and treatment efficacy.

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Hospitals represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes e- hospitals, ambulatory surgical centers, and others. According to the report, hospitals represented the largest segment.

The hospitals segment is driven by the increasing demand for advanced medical devices and technologies to enhance patient care, optimize clinical outcomes, and improve operational efficiency. Hospitals are investing in state-of-the-art equipment such as imaging systems, surgical robots, and patient monitoring devices to meet the growing healthcare needs of their patient populations. Additionally, the adoption of electronic health records (EHRs) and health information systems is on the rise, driven by the need for integrated data management solutions that streamline workflows, facilitate informed decision-making, and ensure compliance with regulatory requirements. Furthermore, hospitals are prioritizing investments in infection control and patient safety measures, spurred by the ongoing challenges posed by healthcare-associated infections (HAIs) and the need to mitigate risks in clinical environments. This includes the implementation of advanced disinfection technologies, antimicrobial surfaces, and real-time monitoring systems to prevent the spread of infections and safeguard patient well-being.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest drug device combination products market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for drug device combination products.

The North American region is driven by the increasing prevalence of chronic diseases, such as diabetes, CVDs, and cancer. With a growing aging population and sedentary lifestyles contributing to the rise in chronic conditions, there's a heightened demand for innovative treatment solutions. This trend fuels the adoption of drug device combination products that offer enhanced efficacy and convenience in managing these complex health issues. Additionally, the region benefits from robust regulatory frameworks and streamlined approval processes, facilitating the development and commercialization of new combination therapies. Moreover, strategic collaborations between pharmaceutical companies, medical device manufacturers, and research institutions drive innovation and accelerate the pace of product development in North America. These collaborations leverage the region's strong research infrastructure and expertise to address unmet medical needs and capitalize on emerging market opportunities. Furthermore, the increasing healthcare expenditure in North America supports market growth by improving accessibility to advanced combination therapies and fostering investment in research and development initiatives.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the drug device combination products industry include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The key players in the drug device combination products market are actively engaged in strategic initiatives to maintain their competitive edge and drive market growth. These initiatives include extensive research and development (R&D) efforts aimed at introducing novel combination therapies that offer improved therapeutic outcomes and patient convenience. Additionally, companies are focusing on expanding their product portfolios through acquisitions, partnerships, and collaborations with other industry stakeholders. These strategic alliances enable companies to leverage complementary expertise, technologies, and resources to accelerate product development and market penetration. Moreover, key players are investing in marketing and promotional activities to raise awareness about their products and enhance their market presence. Furthermore, efforts are being made to strengthen regulatory compliance and quality assurance processes to ensure product safety and efficacy. Additionally, companies are exploring opportunities in emerging markets by establishing local manufacturing facilities and distribution networks to cater to the growing demand for combination products in these regions.

Drug Device Combination Products Market News:

  • In June 2020: Abbott announced the launch of its new drug device combination product, the FreeStyle Libre 2 system, in the United States. This system integrates Abbott's continuous glucose monitoring (CGM) technology with a wearable sensor and a mobile app, allowing individuals with diabetes to monitor their glucose levels continuously without the need for fingerstick tests. The FreeStyle Libre 2 system offers improved accuracy and reliability compared to previous models, providing patients with real-time insights into their glucose levels and helping them make more informed decisions about their diabetes management.
  • In August 2020: Medtronic announced the FDA approval of its MiniMed 770G insulin pump system for use in children aged 2 to 6 years with type 1 diabetes. This drug device combination product combines an insulin pump with a continuous glucose monitoring (CGM) system, enabling automated insulin delivery based on real-time glucose readings. The MiniMed 770G system features advanced algorithms that help stabilize blood sugar levels and reduce the risk of hypoglycemia in young children, providing caregivers with peace of mind and improving the overall management of pediatric diabetes.

Key Questions Answered in This Report:

  • How has the global drug device combination products market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global drug device combination products market?
  • What is the impact of each driver, restraint, and opportunity on the global drug device combination products market?
  • What are the key regional markets?
  • Which countries represent the most attractive drug device combination products market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the drug device combination products market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the drug device combination products market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the drug device combination products market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global drug device combination products market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Drug Device Combination Products Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Drug Eluting Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Transdermal Patches
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Infusion Pumps
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Drug Eluting Balloon
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Inhalers
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Cardiovascular
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diabetes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cancer Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Respiratory Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Baxter International Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Boston Scientific Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Smith & Nephew plc
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Stryker Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Terumo Corporation
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Drug Device Combination Products Market: Major Drivers and Challenges
  • Figure 2: Global: Drug Device Combination Products Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Drug Device Combination Products Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Drug Device Combination Products Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Drug Device Combination Products Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Drug Device Combination Products Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Drug Device Combination Products Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Drug Device Combination Products (Drug Eluting Stents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Drug Device Combination Products (Drug Eluting Stents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Drug Device Combination Products (Transdermal Patches) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Drug Device Combination Products (Transdermal Patches) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Drug Device Combination Products (Infusion Pumps) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Drug Device Combination Products (Infusion Pumps) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Drug Device Combination Products (Drug Eluting Balloon) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Drug Device Combination Products (Drug Eluting Balloon) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Drug Device Combination Products (Inhalers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Drug Device Combination Products (Inhalers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Drug Device Combination Products (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Drug Device Combination Products (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Drug Device Combination Products (Cardiovascular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Drug Device Combination Products (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Drug Device Combination Products (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Drug Device Combination Products (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Drug Device Combination Products (Cancer Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Drug Device Combination Products (Cancer Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Drug Device Combination Products (Respiratory Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Drug Device Combination Products (Respiratory Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Drug Device Combination Products (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Drug Device Combination Products (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Drug Device Combination Products (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Drug Device Combination Products (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Drug Device Combination Products (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Drug Device Combination Products (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Drug Device Combination Products (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Drug Device Combination Products (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: North America: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: North America: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: United States: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: United States: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Canada: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Canada: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Asia-Pacific: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Asia-Pacific: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: China: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: China: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Japan: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Japan: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: India: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: India: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: South Korea: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: South Korea: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Australia: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Australia: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Indonesia: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Indonesia: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Others: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Europe: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Europe: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Germany: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Germany: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: France: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: France: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: United Kingdom: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: United Kingdom: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Italy: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Italy: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Spain: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Spain: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Russia: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Russia: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Latin America: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Latin America: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Brazil: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Brazil: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Mexico: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Mexico: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Middle East and Africa: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Middle East and Africa: Drug Device Combination Products Market: Breakup by Country (in %), 2023
  • Figure 84: Middle East and Africa: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Global: Drug Device Combination Products Industry: SWOT Analysis
  • Figure 86: Global: Drug Device Combination Products Industry: Value Chain Analysis
  • Figure 87: Global: Drug Device Combination Products Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Drug Device Combination Products Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Drug Device Combination Products Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Drug Device Combination Products Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Drug Device Combination Products Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Drug Device Combination Products Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Drug Device Combination Products Market: Competitive Structure
  • Table 7: Global: Drug Device Combination Products Market: Key Player